The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Jaume Capdevila
No relevant relationships to disclose
Jose Manuel Trigo Perez
No relevant relationships to disclose
Javier Aller
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
Silvia Garcia Adrian
No relevant relationships to disclose
Carles Zafon
No relevant relationships to disclose
Òscar Reig
No relevant relationships to disclose
Uriel Bohn
No relevant relationships to disclose
Elena Cillan
No relevant relationships to disclose
Manuel Duran
No relevant relationships to disclose
Beatriz Gonzalez Astorga
No relevant relationships to disclose
Ana Lopez
No relevant relationships to disclose
Medina Javier
No relevant relationships to disclose
Ignacio Porras
No relevant relationships to disclose
Juan J Reina
No relevant relationships to disclose
Nuria Palacios
No relevant relationships to disclose
Enrique Grande
No relevant relationships to disclose
Juan J. Grau
No relevant relationships to disclose